Compare ResMed Inc. (RMD) vs Weibo Corp (WB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Weibo Corp — how do they compare? ResMed Inc. trades at $225.92 (market cap $31.89B), while Weibo Corp trades at $6.51 (market cap $1.56B). The key difference: ResMed Inc. is far larger — about 20.4× Weibo Corp's market cap, and Weibo Corp pays the higher dividend (9.47%). Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and Weibo Corp for 102 Days on average.
| RMD | WB | |
|---|---|---|
Market Cap | $31.89B | $1.56B |
Volume | 618,314 | 812,503 |
Sector | Health | Media |
52-Week High | $277.88 | $12.37 |
52-Week Low | $182.82 | $6.33 |
Typical Hold Time | 51 Days | 102 Days |
Enterprise Value | $31.24B | $786.69M |
Dividend Yield | 1.16% | 9.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $225.98, up 2.4% today, with a bullish technical signal and strong fundamentals. Revenue grew to $5.15B in 2025, with net income at $1.40B and a 26.94% net margin. Recent earnings beats and a 12-14% EPS growth outlook support momentum. The stock is near its pivot point of $227, with support at $225 and resistance at $228.
Outlook is positive with analyst consensus at Buy and a $242.70 price target. Risks include competitive pressures and ongoing legal investigations. Institutional buying and solid cash flow growth underpin the bullish case, though macroeconomic and regulatory factors warrant monitoring.
Weibo (WB) trades at $6.48, down 0.15% with bearish technical signals. The stock shows attractive valuation metrics including a P/E of 5.36 and P/B of 0.4, while maintaining strong profitability with 73.36% gross margins. Recent earnings show mixed performance with Q2 2026 beating expectations but Q4 2025 and Q1 2026 missing estimates. Cash flow trends indicate volatility with a significant net outflow in 2024 followed by recovery in 2025.
Weibo presents as a deep-value opportunity with compelling valuation multiples, though growth concerns persist amid declining user metrics and advertising challenges. Analyst sentiment remains divided with 40.9% buy ratings versus 45.5% hold, reflecting uncertainty about the company's ability to maintain relevance against intensifying competition in social media.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →
